ClinicalTrials.gg
Not yet recruitingNCT05863845Updated May 18, 2023

Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

An interventional study of Venetoclax and Carmustine in Diffuse Large B Cell Lymphoma, sponsored by Ruijin Hospital. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-18.

Sponsored by Ruijin Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing venetoclax in Lymphoma, Large B-Cell, Diffuse — 4 open to participants now, 8 under way, 1 of them phase 3. venetoclax · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
6th of 17
52 · median 31
Started
2023
with 1 other
No phase
Only one
of the 17
Registered
14th of 17
by date
Lead sponsor
1 of 17
Ruijin Hospital

Among the 17 studies testing venetoclax in Lymphoma, Large B-Cell, Diffuse, this one is the 6th largest by planned enrollment, is one of 2 that started in 2023, is the only one with no phase, and was the 14th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

4 of the 17 studies testing venetoclax in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing venetoclax in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This single-center, randomized clinical study will evaluate the efficacy and safety of Venetoclax combined with BEAM Pretreatment Regimen in ASCT treatment of DLBCL patients.

Read the detailed description

Diffuse Large B-cell lymphoma (DLBCL) is a group of highly heterogeneous aggressive non-Hodgkin lymphomas with different pathogenesis and clinical prognosis. Despite the survival benefits of Anthracycline-based chemotherapy bridging autologous stem cell transplantation (ASCT), 30%-40% of DLBCL patients fail to respond to treatment and relapse or die within a short period of time. A phase I/II trial of Venetoclax combined with BEAM as a pretreatment regimen for ASCT of high-risk and relapsed/refractory lymphoma was presented at the ASH Meeting 2021 (NCT03583424), and it studies the side effects and best dose of venetoclax when given together with BEAM (carmustine, etoposide, cytarabine, and melphalan) before stem cell transplant in treating participants with relapsed or refractorynon-Hodgkin lymphoma. The results confirmed that Venetoclax has a good prospect in ASCT.

03

Conditions studied

  • Diffuse Large B Cell Lymphoma

Keywords

  • LYMPHOMA
  • DLBCL
  • ASCT
  • VENETOCLAX
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. According to world Health Organization (WHO) classification of disease, DLBCL was confirmed by histology, after treatment, and CR or PR after upfront treatment;
  2. 18≤ age ≤65 years old, male or female;
  3. Bcl-2 positive rate >50% according to immunohistochemistry of biopsied tissue;
  4. No serious organic lesions in the main organs, meeting the requirements of the following laboratory examination indicators (conducted within 7 days before treatment) :

    • White blood cell count ≥3.0×109/L, ≥1.5×109/L, ≥90g/L, ≥75×109/L;
    • Total ≤1.5× upper normal value ();
    • (AST) and alanine aminotransferase (ALT) ≤2.5× upper normal value (ULN);
    • was 44-133 mmol/L;
  5. score 0-1;
  6. The subject or his/her legal representative must provide written prior to conducting a special study examination or procedure.

Exclusion criteria

Exclusion Criteria:

  1. Previously received hematopoietic stem cell transplantation;
  2. Suffering from serious complications or severe infection;
  3. Previously treated with Venetoclax;
  4. Central nervous system lymphoma was excluded; Suffering from serious complications or severe infection;
  5. A history of other malignant tumors within 5 years, excluding early tumors treated for curative purposes;
  6. Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases, etc.;
  7. , or positive. Positive HBV and HCV serology is allowed, but DNA/RNA testing must be negative;
  8. Laboratory test value during screening;

    • Neutrophils \<1.5×109/L; \<75×109/L;
    • was 1.5 times higher than the normal upper limit, transaminase was 2.5 times higher than the normal upper limit;
    • The creatinine level is higher than 1.5 times the value;
  9. ≦ 50%;
  10. Other concurrent and uncontrolled medical conditions considered by the investigator would affect the patient's participation in the study;
  11. Psychiatric patients or other patients known or suspected to be unable to fully comply with the study protocol;
  12. Pregnant or lactating women;
  13. The researcher judged that the patients were not suitable for this study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    V-BEAM

    Patients in this arm will receive Venetoclax Combined With BEAM (Carmustine, Etoposide Cytarabine and Melphalan) as Pretreatment Regimen of ASCT. Participants receive Venetoclax PO QD on days -10 to -1, Carmustine IV on day -7, Etoposide IV BID on days -6 to -3, Cytarabine IV BID on days -6 to -3, and Melphalan IV on day -2. Participants then undergo hematopoietic cell transplantation on day 0.

    Drug: Venetoclax · Drug: Carmustine · Drug: Cytarabine · Drug: Etoposide · Drug: Melphalan · Procedure: Hematopoietic Cell Transplantation

  • Sham comparator
    BEAM

    Patients in this arm will receive BEAM (Carmustine, Etoposide Cytarabine and Melphalan) as Pretreatment Regimen of ASCT. Participants receive Venetoclax PO QD on days -10 to -1, Carmustine IV on day -7, Etoposide IV BID on days -6 to -3, Cytarabine IV BID on days -6 to -3, and Melphalan IV on day -2. Participants then undergo hematopoietic cell transplantation on day 0.

    Drug: Carmustine · Drug: Cytarabine · Drug: Etoposide · Drug: Melphalan · Procedure: Hematopoietic Cell Transplantation

Interventions

  • 100mg day -10, 200mg day -9, 400mg day -8, 800mg day -7 to -1, Given PO

  • 300mg/m2 day -7, Given IV

  • 100mg/m2/d, day -6 to day -3, Given IV

  • 200mg/m2/d, day -6 to day -3, Given IV

  • 140mg/m2, day -2, Given IV

  • ProcedureHematopoietic Cell Transplantation

    Undergo hematopoietic cell transplantation

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Progression-free survival was defined as the time from the date of ASCT until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from an cause, whichever occurred first.

    Time frame: Baseline up to data cut-off (up to approximately 2 years)

Secondary outcomes

  1. Overall survival

    Overall survival was defined as the time from the date of ASCT to the date of death from any cause.

    Time frame: Baseline up to data cut-off (up to approximately 2 years)

  2. Complete remission rate

    Percentage of participants with complete response was determined on 2014 Lugano criteria.

    Time frame: Baseline up to data cut-off (up to approximately 2 years)

  3. The time of hematopoietic reconstruction

    The first day of neutrophils ≥0.5×109/L for 3 consecutive days was the time of successful implantation of granulocytes. Platelet ≥20.0×109/L for 7 consecutive days and the first day after platelet infusion was considered as the successful time of megakaryocytes implantation.

    Time frame: Baseline up to data cut-off (up to approximately 2 years)

  4. Transplantation-related adverse reactions

    Transplantation-related adverse reactions are any untoward medical occurrence in a participant which is related to ASCT.

    Time frame: Baseline up to data cut-off (up to approximately 2 years)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2023; primary completion for Nov 2024, 17 months later.

Of 40 non-industry interventional studies with no phase under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 144. This study's planned 17 months is below that.

Counting every sponsor, half of 41 studies reached it within 73 months; a quarter within 42 and three quarters within 137.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2023
First posted
May 18, 2023
StartEst.
Jun 1, 2023
Primary completionEst.
Nov 30, 2024
CompletionEst.
Nov 30, 2025
Last update
May 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05863845
Lead sponsor
Ruijin Hospital
Responsible party
Zhao Weili (Prof., Ruijin Hospital) — Principal investigator
First posted
May 18, 2023
Start date
Jun 1, 2023 (estimated)
Primary completion
Nov 30, 2024 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
May 18, 2023

Study contacts

Weili Prof. Zhao
Contact
zwl_trial@163.com
+862164370045 ext. 610707
Pengpeng Prof. Xu
Contact
pengpeng_xu@126.com
+862164370045

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion